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ABSTRACT 
An increasing number of studies have shown an inverse association between a personal 
history of cancer (PHC) and dementia/Alzheimer’s disease (AD), both in those using 
dementia/AD as the outcome or cancer as the outcome. This is the first study to examine this 
potential association in Japanese Americans; and to examine family history of cancer and its 
association with incident dementia. Also, the association between these two diseases in the 
parents of participants were analyzed.  
The Kame Project, conducted from 1992 through 2001 in King County, Washington was 
a population-based, prospective cohort study of older Japanese Americans. Conversion to 
incident dementia was observed throughout the follow-up period and diagnosed by standard 
criteria in a consensus conference. 
A PHC did not have a significant association with the development of dementia. 
Differences between this study and those conducted previously showing an inverse association 
between cancer and dementia or AD included a lower age of the present cohort, race/ethnicity, 
focus on all-cause dementia vs. AD and adjustment for the competing risk of death. A family 
history of cancer was inversely associated with the development of dementia. There were 
statistically significant trends for a dose-response association between the numbers of affected 
relatives with cancer and risk for dementia. The findings are most likely explained by an inverse 
genetic association between cancer and dementia. Older Japanese Americans (the parents) with a 
history of cancer were nearly 2.5 times less likely to have a history of dementia than those 
without a cancer history.  
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CHAPTER ONE: 
THE ASSOCIATION BETWEEN A PERSONAL HISTORY OF CANCER AND 
INCIDENT DEMENTIA IN JAPANESE AMERICANS: THE KAME PROJECT 
 
Introduction 
There is a growing body of epidemiologic evidence supporting a protective effect for 
cancer survivors in the development of AD.1-3 The three cited, recently conducted meta-analyses 
all show approximately a one-third reduced risk for the development of AD. 
The evidence for an inverse association among all-cause dementia is less robust. A 
nested-case control study in Sweden showed an inverse association among all cancer types and 
dementia.4 However, two prospective studies (the Framingham Heart Study and Einstein Aging 
Study) reported hazard ratios (HR) below one, but their findings were not statistically 
significant.5, 6 
The current study is the first to investigate the relationship between cancer and dementia 
among Japanese Americans. Our a priori hypothesis was that there would be an inverse 
association between a personal history of cancer (PHC) and incident dementia in this population. 
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Methods 
Study Population 
The Kame Project was a prospective cohort study of older Japanese Americans in King 
County, Washington from 1992 through 2001. The baseline examination was completed by 
1,985 of 3,045 cohort eligible participants (65.2%) who were at least 65 years old (Figure 1.1). 
The number of prevalent dementia cases was 150, and 190 participants were lost to follow-up. 
The baseline questionnaire, given by an interviewer and completed by either the participant or 
their proxy, included a section on personal medical history. This section included information on 
various diseases, including cancer and stroke. The methods, prevalence and incidence have been 
described in detail previously.7, 8 For the current analyses, only participants who were dementia-
free at baseline were included. There were insufficient data on history of cancer for 100 
participants and on a history of stroke for 5 participants. Furthermore, 22 participants were 
missing data on history of smoking in the sub-analysis. All participants gave written informed 
consent, and the study was approved by the University of Washington and University of South 
Florida Institutional Review Boards. 
 
Dementia Case Ascertainment 
 Participant follow-up continued throughout four biennial waves.8 Incident dementia cases 
were assessed through repeated screenings of the Cognitive Abilities Screening Instrument 
(CASI). When a participant scored 86 of 100 or less on the CASI, they were asked to return with 
a proxy informant. At that time, the potential case underwent detailed neuropsychological testing 
and received a workup by study clinicians, including laboratory testing and imaging if deemed 
necessary. Diagnoses were made by a consensus conference using DSM-IV criteria for 
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dementia.9 Each case was also sub-classified as vascular dementia (VaD) or Alzheimer’s disease 
(AD) if they met the criteria.10, 11 If they did not meet DSM-IV criteria for dementia, they were 
placed back in the non-demented cohort and followed biennially. The current analysis 
investigates all-cause dementia as the outcome. 
 
Covariate Ascertainment 
The personal history questionnaire asked participants if they had been diagnosed with 
cancer other than skin cancer. Previous and current cancers were combined into one composite 
cancer variable. All covariates were dichotomized, History of cancer and history of stroke were 
coded either yes or no; Education was divided into those with 12 years of education or less and 
those with more than 12 years of education.  Smoking was dichotomized into ever (currently or 
in the past) versus never smoking. The investigation of comorbidities (including histories of 
Type II diabetes, coronary heart disease and hypertension, which were not associated with 
dementia and excluded from the final models)6, 12-14 and smoking5, 13, 14 is consistent with 
previous cancer-dementia studies.   
 
Statistical Analyses 
 All independent variables analyzed were assessed at baseline. Baseline characteristics 
(sex, education, history of smoking, history of stroke and survival status) were compared by 
PHC status using the chi-square test. The Student’s t-test was used for baseline age. A p-value 
below 0.05 was considered statistically significant for both tests. Age was used as the time scale 
in survival analyses. For non-demented participants, the difference between their baseline age 
(left-truncation) and their age at loss to follow-up, death or study end (right-censoring) was used 
  
4 
 
to determine their contribution to person-years. For demented participants, their dementia age 
was calculated as the midpoint between their previous examination and the one at which their 
diagnosis occurred.  
We used Fine-Gray proportional hazard regression models15 to obtain hazard ratios and 
95% confidence intervals for PHC adjusted for age at baseline, sex, education and history of 
stroke in model 1, and additionally for history of smoking in model 2. Both models took into 
account the competing risk of death (survival status). The models used the left-truncation of 
baseline age. The data were analyzed using SAS 9.4 (SAS Institute Inc., Cary, NC).  
Written informed consent was obtained from all of the Kame cohort participants included 
in the current study. The Kame Project was approved by the University of Washington and 
University of South Florida Institutional Review Boards. 
 
Results 
 Cancer prevalence among the cohort was 9.9% (n = 153), with the remaining 1,387 
participants cancer-free at baseline (Table 1.1). There were 172 cases of all-cause incident 
dementia in the original Kame cohort,8 but due to missing data for history of cancer and history 
of stroke, there were 145 cases (9.4%) in the current analysis. Of these 145 cases, there were 115 
cases of AD and 45 cases of VaD. These subtypes are not mutually exclusive, as an individual 
can have more than one subtype. The sample consisted of 863 (56.0%) women; 538 (38.8%) of 
the participants had more than 12 years of education; 44 participants (3.2%) had had a stroke; 
and 749 (48.6%) were ever smokers. The overall average age at baseline was 71.9 years (SD = 
5.5) for participants without a history of cancer and 72.8 years (SD = 5.2) for those with a history 
of cancer. There were no statistically significant differences between participants with and 
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without a history of cancer for any of these variables. There was a statistically significant 
difference (P <0.01) for survival status at the end of the study period.  
 Table 1.2 shows the univariate analysis and final multivariate models (Model 1 and 2). 
The univariate hazard ratio for dementia associated with a PHC was 1.07 (95% CI = 0.65-1.76). 
Covariates that statistically significantly associated with the development of dementia in the 
crude analysis included education (HR = 0.62, 95% CI = 0.42-0.90) and history of stroke (HR = 
2.18, 95% CI = 1.09-4.37). In Model 1, the association between PHC and incident dementia was 
HR = 1.13 (95% CI = 0.69-1.86). Education (HR = 0.63, 95% CI = 0.42-0.94) and history of 
stroke (HR = 2.14, 95% CI = 1.05-4.32) were independently associated with dementia. The 
addition of history of smoking to the second model attenuated the potential association with 
dementia (HR = 1.06, 95% CI = 0.63-1.79). In this model, education and history of stroke were 
no longer statistically significant. 
Age-specific risks for dementia are shown in Table 1.3. Participants who were age 70 or 
younger at baseline showed a higher point estimate (HR = 3.01) in Model 1 and (HR = 2.02) in 
Model 2 than those older than 70 (HR = 0.96) and (HR = 0.94), respectively. However, 
differences between age-specific HRs were not statistically significant. We also tested whether 
those who survived to the end of the study had a different adjusted hazard ratio from those who 
died during the study and did not find significant differences between these groups. 
 
Discussion  
The results from this population-based, prospective cohort study did not show that having 
had cancer was inversely associated with the development of dementia. Although there was a 
tendency for younger participants to show an increased positive association between PHC and 
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incident dementia than older participants, neither of the point estimates was statistically 
significant and the test for interaction between age group and personal cancer history did not 
reveal a significant difference. Furthermore, we did not see a significant difference between the 
hazard ratios in those who survived to the end of the study and those who died.   
Our findings of no protective effect of personal cancer history on the risk of dementia 
need to be interpreted in the context of a substantial number of studies that showed significant 
inverse associations between cancer history and dementia or AD risk.5, 6, 13, 14, 16 Because 
dementia and death from cancer represent competing risks, apparent protective associations can 
occur if individuals who are destined to develop AD die of cancer before manifesting dementia, 
while those without cancer are not selected in the same manner. In the present analyses, we used 
Fine-Gray proportional hazards regression to address the issue of competing risk of death.  
Previous studies have not addressed the competing risk of death. However, Driver et al.5 
restricted their sample to individuals who survived to at least 80 and did not see a significant 
difference between the HR obtained in that sample and the entire sample that included people 
with earlier mortality. We also did not find a significantly different hazard ratio in participants 
who were younger versus those who were older at baseline, as might be expected if differential 
survival of those with cancer was playing an important role. The point estimate for younger 
participants, however, was lower than that for older participants. Other studies also have shown 
stronger inverse associations for older participants.4, 16 
Two significant differences between our cohort and those of studies showing significant 
protective effects are age and race. The mean age in the Kame Project was 71.9 years. The 
Framingham Heart Study cohort5 had the same minimum age, but mean age at baseline for those 
without cancer was 76 years and with cancer, 77 years. The Bronx Aging Study6  reported a 
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mean age at baseline of 78.6 for dementia-free participants and 80.7 years for all-cause dementia, 
with study entry also set at 65. Given that participants in the Kame Project were younger, the 
higher mean age in the other studies’ may have led to a greater chance of finding an inverse 
association between a PHC and incident dementia due to a stronger competing risk of mortality 
at higher ages.   
The increased point estimate observed in the Kame Project is similar to a previous study 
that included African Americans. The Cardiovascular Health Study-Cognition Sub-study of 
participants from California, North Carolina, Maryland and Pennsylvania separately analyzed 
data on minorities (n = 232), of whom most were African American.6  In this sub-sample, the HR 
between cancer and incident VaD and AD  was2.57 (95% CI = 1.27-5.23). Most previous studies 
have focused on European or European American populations. The results from the present study 
of Japanese Americans, when taken into account with the results from African Americans, may 
indicate a difference between ethnic groups, particularly in the US.  
Another possible reason that we did not observe an inverse association is that we did not 
ascertain the presence of skin cancer. The questionnaire asked about the presence of cancer, 
excluding skin cancer. Skin cancer is often subdivided into melanoma and non-melanoma skin 
cancer (NMSC). NMSC is the most common form of cancer, of which the most commonly 
occurring types are basal-cell carcinoma and squamous-cell carcinoma.17 Some of the previous 
studies on cancer and incident dementia included or excluded melanoma and/or NMSCs. The 
Einstein Aging Study in the Bronx, reported a null association between all cancers and any 
dementia (HR = 0.85, 95% CI = 0.56-1.29), while a separate model consisting exclusively of 
NMSC cancers yielded a more inverse result that was also not statistically significant (HR = 
0.68, 95% CI = 0.35-1.31).6 The Swedish nested-case control study of registry data (N = 
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167,080; 19,756 cases) included multiple types of cancers, and treated melanoma and NMSCs 
separately.4 Their findings for all cancers (HR = 0.60, 95% CI = 0.52-0.69) fell in between that 
of melanoma (HR = 0.44, 95% CI = 0.20-0.97) and NMSCs (HR = 0.77, 95% CI = 0.58-1.04). 
We also relied on self-reporting of cancers which is consistent with previous epidemiologic 
studies investigating cancer and incident dementia and AD.6, 18, 19 
 A final possible limitation of our findings was the inclusion of vascular and Alzheimer 
cases in the outcome of all-cause dementia. Other studies have reported stronger inverse 
associations in Alzheimer’s versus other types of dementia.5, 6, 13 However, given that two-thirds 
of cases carried a diagnosis of AD, the inclusion of vascular dementia cases is unlikely to have 
completely eliminated an inverse association.   
An additional strength of our study was the prospective and uniform identification of 
dementia cases.  Some previous studies relied on the use of clinical or registry data.4, 16 The 
clinical diagnosis of dementia and its subtypes was made by a consensus committee consisting of 
a neurologist, geriatrician, internist, neuropsychologist and epidemiologist using standardized 
research criteria.20  
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Table 1.1. Baseline statistics by cancer status. 
 
  No Cancer (n = 1,387) Cancer (n = 153)   
N = 1,540 No. or mean 
% or 
(SD) No. or mean % or (SD) P 
Age at baseline, y 71.9 (5.5) 72.8 (5.2) 0.45 
Sex         0.70 
   Male 612 44.1 65 42.5   
   Female 775 55.9 88 57.5   
Education         0.92 
   ≤12 years  849 61.2 93 60.8   
   >12 years  538 38.8 60 39.2   
Smoking         0.39 
   Never 688 50.3 81 54.0   
   Ever 680 49.7 69 46.0   
Stroke         0.20 
   No 1,343 96.8 151 98.7   
   Yes 44 3.2 2 1.3   
Survival status         <0.01 
   Survivors 1,183 85.3 117 76.5   
   Nonsurvivors 204 14.7 36 23.5   
 
 
Table 1.2. Results of Fine-Gray Cox proportional hazards models testing unadjusted covariates 
with dementia outcome and testing the final model. 
 
N = 1,540 No   Dementia   Univariate Model 1* Model 2* 
Predictor dementia (n) diagnosis (n) HR (95% CI) HR (95% CI) HR (95% CI) 
Cancer       N = 1,540 N = 1,518 
   No 1,260 127 1.00 1.00 1.00 
   Yes 135 18 1.07 (0.65-1.76) 1.13 (0.69-1.86) 1.06 (0.63-1.79) 
Sex           
   Male 620 57 1.00 1.00 1.00 
   Female 775 88 1.17 (0.84-1.64) 1.09 (0.77-1.55) 1.10 (0.70-1.73) 
Education           
   ≤12 years  833 109 1.00 1.00 1.00 
   >12 years  562 36 0.62 (0.42-0.90)† 0.63 (0.42-0.94)† 0.67 (0.45-1.01) 
Smoking           
   Never 697 72 1.00 *** 1.00 
   Ever 687 62 1.06 (0.76-1.49) *** 1.12 (0.73-1.73) 
Stroke           
   No 1,359 135 1.00 1.00 1.00 
   Yes 36 10 2.18 (1.09-4.37)† 2.14 (1.05-4.32)† 2.06 (0.99-4.30) 
*Model 1 adjusted for age at baseline, cancer, sex, education and stroke. Model 2 additionally controls for 
smoking.  †P < 0.05 
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Table 1.3. Age-specific risks by baseline age group. 
 
  Model 1   Model 2 
n HR (95% CI) n HR (95% CI) 
655 3.01 (0.80-11.3) 652 2.02 (0.41-10.1) 
885 0.96 (0.57-1.64) 866 0.94 (0.54-1.64) 
1,518 1.13 (0.69-1.86) 1,518 1.06 (0.63-1.79) 
Abbreviations: HR = hazard ratio; CI = confidence interval 
 
 
 
 
Figure 1.1.  Participant flow chart. 
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CHAPTER TWO: 
FAMILY HISTORY OF CANCER IS INVERSELY ASSOCIATED WITH DEMENTIA. 
THE KAME PROJECT 
 
Introduction  
 A personal history of cancer has been shown in some studies to be inversely associated 
with incident dementia4-6, 13 as well as Alzheimer’s disease (AD).1-3 Because people with a 
personal history of cancer may have a higher risk of dying before manifesting dementia than 
those without such a history, inverse associations could be the result of survival bias. 
Furthermore, individuals with impending dementia may be less likely to have their cancer 
diagnosed promptly.21 If the association is real and is genetically-determined, individuals with 
dementia would be less likely to have a family history of cancer in close blood relatives. To 
address this issue, we assessed whether a family history of cancer is associated with risk of 
incident dementia. To our knowledge, this is the first time this question has been addressed. 
 
Methods 
Study Population 
Participants were from the Kame Project, a population-based prospective cohort study of 
Japanese Americans aged 65 and older residing in King County, Washington between 1992 and 
the end of 2001.7, 8 The baseline questionnaire was completed by 1,835 dementia-free 
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participants. Participants were asked to complete a family tree diagram of first-degree relatives 
before arriving for their first visit at the study site. Each diagram was transposed by the 
interviewer into the questionnaire. Data were collected on each family member concerning 
whether or not each family member had cancer or experienced memory problems. Of those who 
completed the baseline examination, 190 (10.4%) were lost to follow-up and 160 (8.7%) were 
excluded from the analysis due to insufficient data (100 for personal history of cancer, 55 for 
family history of cancer and 5 for personal history of stroke) (Figure 2.1). The sample size for 
the current analysis was 1,481.  
Each family member from the questionnaire was uniquely identified. Relatives for whom 
data on family history of cancer and dementia were collected included parents, full- and half-
siblings. Children were excluded from the analysis as few had reached high risk ages for cancer 
and dementia.  
Written informed consent was obtained from all of the Kame cohort participants included 
in the current study. The Kame Project was approved by the University of Washington and 
University of South Florida Institutional Review Boards. 
 
Dementia Case Ascertainment 
Participant follow-up continued throughout four biennial waves. Methods for diagnosis 
are detailed elsewhere.7, 8 Briefly, incident cases were assessed through repeated screenings of 
the Cognitive Abilities Screening Instrument (CASI). When a participant scored 86 of 100 or 
less on the CASI, they were asked to return for a second examination with a proxy informant. At 
this time, the potential case underwent detailed neuropsychological testing and was worked up 
by a study clinician. A consensus diagnosis was later performed. If the potential case met DSM-
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IV criteria for dementia, they became an incident dementia case.9 Each case was also sub-
classified Alzheimer’s disease,11 vascular dementia (VaD)10 or other dementias.  If a potential 
case did not meet DSM-IV criteria for dementia, they were placed back in the non-demented 
cohort and followed biennially. This study investigated all-cause dementia as the outcome.  
 
Cancer Case Ascertainment 
The personal history questionnaire asked Kame participants if they had been diagnosed 
with cancer, with the exception of skin cancer. Previous and prevalent cancers were combined 
into one composite cancer variable. Kame Project participants were asked for each first degree 
relative, whether or not they had been diagnosed with cancer, leukemia and Hodgkin’s disease. 
These three questions were combined into one derived variable for analyses. The family cancer 
history variable was classified three different ways: 1) 0 vs. ≥1; 2) 0 vs. 1 vs. ≥2; 3) 0 vs. 1 vs. 2 
vs. ≥3. 
 
Covariate Ascertainment 
 The baseline questionnaire collected data on personal characteristics, including family 
size, sex, age (years), education (years), personal history of smoking and personal health history 
of stroke. Age at baseline and family size (excluding the participant) were treated as continuous 
variables. Education was dichotomized into 12 years or less and more than 12 years. Personal 
history of smoking was defined as ever (current or past) or never. A personal history of stroke 
was diagnosed by a physician were endorsed as Yes or No. 
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Statistical Analyses 
 Baseline variables were compared by family history of cancer status (yes or no). 
Comparisons used the chi-square test for dichotomous variables and the Student’s t-test for 
continuous variables. These same covariates were analyzed separately to determine their crude 
association with the outcome using Fine-Gray proportional hazard regressions.  
 All Fine-Gray regression models used age as the time scale.15 For non-demented 
participants, the difference between their baseline age (left-truncation) and their age at loss to 
follow-up, death or study end (right-censoring) was used to determine their person-years 
contribution. For demented participants, their dementia age was calculated as the midpoint 
between their previous examination and the one at which their diagnosis occurred. Univariate 
and multivariate statistics presented in the tables include the hazard ratio (HR) point estimate and 
95% confidence interval. For disease status, the absence of the condition is the reference 
category. Men formed the reference group for sex and 12 years or less for education. Covariates 
in the final models included family history of cancer, age, sex, education, family size, personal 
history of cancer, personal history of smoking and personal history of stroke. A separate final 
model was run for each classification of family history of cancer and a P value for trend was 
obtained. The data were analyzed using SAS 9.4 (SAS Institute Inc., Cary, NC).  
 
Results 
There were 680 participants with no family history of cancer versus 805 participants with 
at least one affected FDR (Table 2.1). Women represented a majority of the sample, with a 
significant difference (P = 0.03) between the cancer groups in chi-square testing. Participants 
with a family history of cancer had a larger family size (mean = 6.67, SD = 2.36) versus those 
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without, mean = 6.02, SD = 2.14, P = <0.01); women represented a higher proportion among this 
group (P <0.05). 
Of participants with a family history of cancer, 7.1% developed dementia versus 10.3% 
without a family history of cancer (Table 2.2). Demented and non-demented participants differed 
by family history of cancer, education and personal history of stroke (P <0.05) in Model 1. The 
first model only dichotomized (two classification levels) family history of cancer.  
 Table 2.3 shows the results of the final models for risk of all-cause dementia for each 
family history of cancer classification. In Model 1, compared to participants without a family 
history of cancer, those with at least one affected first degree relative had a reduced likelihood of 
developing dementia (HR = 0.63, 95% CI = 0.44-0.91, P = 0.01). Participants with two or more 
affected first degree relatives in Model 2 also had a reduced likelihood for dementia (HR = 0.54, 
95% CI = 0.31-0.91) (P trend=0.04). Model 3 also showed a significant trend toward reduced 
dementia risk with increasing numbers of first-degree relatives with cancer (P trend = 0.04), 
particularly among participants with three or more affected first degree relatives (HR = 0.28, 
95% CI = 0.09-0.83).   
 Across all multivariate models, the inverse association with education weakened slightly 
as more family history of cancer classifications were added. Family history of dementia, personal 
history of coronary heart disease and hypertension, family history of stroke, Type II diabetes, 
coronary heart disease and hypertension did not improve the fit of the model. We conducted an 
additional analysis using data on Apolipoprotein (APOE), the major known polymorphism 
associated with increased risk for Alzheimer’s disease, which was available for a majority of 
participants. Adjusting for APOE, there was no change in the model, indicating that it was 
neither a confounder nor an effect modifier. Therefore, it was excluded from the final model.  
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Discussion 
 We found that a family history of cancer reduced the risk for incident dementia by about 
one-third among Japanese Americans age 65 and over. There was also a significant trend for a 
dose-response effect when family history of cancer was analyzed by the number of affected first-
degree relatives. The statistical significance of the trend was strongest when the family history of 
cancer variable was dichotomized, weakening slightly as the study’s ability to detect differences 
due to lower power was limited. To our knowledge, this is the first evidence that family history 
of cancer is inversely associated with an individual’s risk of developing dementia.  
Previous studies addressing personal history of cancer and all-cause incident dementia 
found inverse associations.4-6, 12, 13, 16, 19, 22 Published meta-analyses based on these studies 
showed that personal history of cancer was associated with a marked reduction in risk of  
AD.2, 3, 23 In a second paper and in the present analyses, we found that personal history of cancer 
was not associated with dementia risk.  
No definitive biologic mechanism has been identified in the cancer-dementia association. 
Recent research has postulated that cell cycle deregulation may cause cells to exhibit a 
preference for either cell proliferation or cell degeneration (apoptosis).24-27 The three genetic 
factors garnering the most intensive research interest are the peptidyl-prolyl cis-trans isomerase 
nima-interacting 1 (PIN1) tumor suppressor, the tumor protein p53 (p53) enzyme and the 
wingless-type murine-mammary tumor virus integration site (Wnt) signaling pathway.24-27 The 
up-regulation/over-expression of PIN1, the up-regulation of Wnt and/or the down-regulation of 
p53 can cause cell proliferation and lead to cancer, with the reverse being true for cell apoptosis 
and AD.25-28  All are associated with τ protein and Aβ plaques. Stressors cause Aβ accumulation, 
leading to the activation of p53, followed by τP aggregation and finally neuronal death.27, 28 PIN1 
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is involved in τP dephosphorylation and Aβ accumulation.28 The under-expression of PIN1 sets 
off two progressions: the overproduction of Aβ-42 causes the accumulation of plaques leading to 
the development of AD; and τP aggregation creates NFT leading to the development of AD.29 
The inactivation of the Wnt pathway causes Aβ induced neurotoxicity.28 These cell cycle 
alterations leading to AD pathogenesis or oncogenesis are indicative of shared genetic pathways 
between cancer and dementia/AD.  
Both cancer and AD pathogenesis can be modified by epigenetic mechanisms such as 
aging, environmental toxins, diet and exercise.30, 31 All of these are known to be risk factors 
associated with cancer and dementia. Epigenetic mechanisms affect changes in the cell’s 
biology, interfering with the normal cell cycle.27 Additionally, both DNA damage and oxidative 
stress are biological factors inherent to aging, and thus factors relevant to the development of 
cancer and dementia.25 For example, oxidative stress from the aging process causes a down-
regulation of PIN1 leading to the buildup of AD pathology.29   
It is of interest that family history of cancer and not personal history of cancer was 
associated inversely with dementia risk in this study. Associations of personal history of cancer 
with genes known to regulate both oncogenesis and apoptosis may be weak in comparison with 
specific oncogenes with a more direct connection with the cancer but without an effect on 
apoptosis. On the other hand, specific genes know to regulate both oncogenesis and apoptosis, 
such as PIN1, p53 and GSK-3, may have inverse effects in AD and cancer. Polymorphisms for 
each of these genes have been shown to be related to both cancer and AD.  
Family history of a condition can be a protective or a risk factor for a disease, and has 
important public health significance.32 It is possible that our results reflect a genetic biomarker or 
biologic mechanism that confers protection against dementia for people from a cancer-prone 
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family. The up- or down-regulation of PIN1, p53 and Wnt cause an individual’s cells to begin 
oncogenesis (cancer) or apoptosis (AD). All three play a role in the accumulation of beta-
amyloid, the aggregation of tau protein and neuronal death.27, 28 Both disease pathologies are 
modifiable by epigenetic mechanisms, including those integral to the aging process.29, 33, 34 
The current study has important limitations. The derived cancer variable for FDRs 
included all forms of cancer while the personal cancer history excluded skin cancers. One 
previous study found a statistically significant inverse association between melanoma and 
incident dementia (HR = 0.44, 95% CI = 0.20-0.97)4 while previous studies of non-melanoma 
skin cancers and incident dementia found insignificant results.4, 6 However, the incidence of skin 
cancer among Japanese and Japanese Americans is lower than that of Americans.35 This study 
relied on the self-report of cancer, but previous epidemiologic studies investigating cancer and 
incident dementia and AD also did.6, 18, 19 We adjusted for family size to account for the tendency 
of larger families to have more members who develop cancer, but did not adjust for age of the 
relatives at baseline or age of death of the parents, both of which could be related to incidence of 
cancer and AD.    
The greatest contribution of this research is that our study marks the first time that family 
history of cancer has been investigated in relation to incident dementia. Family history of disease 
is indicative of shared genetic, environmental or behavioral risk factors, and has important 
implications for public health research. Family history can be considered as a surrogate for a 
potential biomarker or set of biomarkers.  
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Table 2.1. Baseline comparison between family history of cancer groups, the Kame project. 
 
No Family Family 
 
 
History of 
Cancer 
History of 
Cancer 
 Baseline Statistics     (N = 1,485) (n = 680) (n = 805) P-Value 
Age at Baseline in years (mean [SD]) 71.98 ± 5.25 71.47 ± 4.87 0.06 
Sex (% female) 52.5 58.1 0.03 
Percent with >12 years of education 42.0 37.7 0.09 
Family Size (mean [SD])* 6.02 ± 2.14 6.67 ± 2.36 <0.01 
Percent of ever smokers 49.9 48.9 0.70 
Percent with history of cancer 9.1 10.6 0.35 
Percent with history of stroke 3.2 2.5 0.38 
Percent of survivors 16.5 13.7 0.13 
*Family size excludes the participant 
    
Table 2.2. Univariate & multivariate hazard ratios (HR) and 95% confidence intervals for 
covariates in Model 1. 
 
N = 1,485 n Dementia (%*) Univariate Multivariate 
      N = 1,485 N = 1,470 
Family history of cancer 
      0 680 71 (10.4) 1 (referent) 1 (referent) 
   ≥1 805 57 (7.1) 0.68 (0.48-0.97) 0.63 (0.44-0.91) 
Sex 
       Male 660 53 (8.0) 1 (referent) 1 (referent) 
   Female 825 75 (9.1) 1.11 (0.78-1.58) 1.11 (0.71-1.75) 
Education 
       ≤12 years  897 95 (10.6) 1 (referent) 1 (referent) 
   >12 years  588 33 (5.6) 0.60 (0.40-0.89) 0.68 (0.44-1.04) 
Family size 1,485 128 (8.6) 1.15 (1.07-1.23) 1.17 (1.09-1.25) 
Personal history of smoking 
      Never 746 65 (8.7) 1 (referent) 1 (referent) 
   Ever 728 59 (8.1) 1.11 (0.78-1.58) 1.20 (0.78-1.85) 
Personal history of cancer 
      No 1,338 111 (8.3) 1 (referent) 1 (referent) 
   Yes 147 17 (11.6) 1.14 (0.69-1.90) 1.13 (0.67-1.89) 
Personal history of stroke  
      No 1,443 120 (8.3) 1 (referent) 1 (referent) 
   Yes 42 8 (19.1) 2.28 (1.08-4.83) 2.45 (1.12-5.36) 
* Row percentages  
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Table 2.3. Hazard ratios and 95% confidence intervals for family history of cancer using 3 
different classifications. 
 
  Model 1* (N = 1,470)   Model 2* (N = 1,470)   Model 3* (N = 1,470) 
Number P = 0.01 Number Ptrend = 0.04 Number Ptrend = 0.04 
0 1 (referent) 0 1 (referent) 0 1 (referent) 
≥1 0.63 (0.44-0.91) 1 0.69 (0.46-1.04) 1 0.69 (0.46-1.04) 
  
≥2 0.54 (0.31-0.91) 2 0.64 (0.36-1.13) 
        ≥3 0.28 (0.09-0.83) 
   *Adjusted for age, death, sex, education, family size, personal cancer history, personal smoking 
history and personal stroke history 
 
 
Figure 2.1.  Participant flow chart. 
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CHAPTER THREE: 
ASSOCIATION IN PARENTS BETWEEN TWO DEADLY DISEASES: CANCER AND 
DEMENTIA. THE KAME PROJECT 
 
Introduction 
 Both cancer and dementia are leading killers of the elderly. A growing number of 
epidemiologic studies demonstrate an inverse association between these two conditions. Cancer, 
a disease of cell proliferation, and dementia, a disease of cell degeneration, appear to share 
common biological mechanisms.  
The earliest reported results exploring the relationship between cancer and incident 
dementia/AD was carried out in Japan.22 This prospective study of 2,222 Hiroshima and 
Nagasaki atomic bomb survivors, a methodologically standardized sister study to the Kame 
Project, for which data are analyzed here, sought to determine risk factors for dementia and its 
subtypes. The investigators reported an unadjusted odds ratio (OR) for AD only (OR = 0.3, 95% 
CI = 0.05-0.98), presenting cancer as a protective factor for AD. However, they did not control 
for any of the other variables they reported on (e.g., sex and age).  
There have been several other studies investigating cancer and incident dementia and/or 
AD. One prospective cohort study drawing on data from the Washington University Alzheimer’s 
Disease Research Center and another in the Bronx, New York both reported an inverse 
association between cancer history and incident dementia in their full models, but neither 
achieved statistical significance.6, 19 A Swedish nested case-control study reported similar 
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results.4 There have been a similar number of studies examining the association between 
dementia/AD history and incident cancer. However, in comparison with the incident dementia 
studies, these achieved statistical significance. A nested-case control study within the 
Framingham Heart Study matched on sex and age reported an inverse relationship, excluding 
non-melanoma skin cancers.5 A Taiwanese retrospective cohort study reported a similar inverse 
association for all cancers.36 
 In the Kame Project, another population of Japanese, living in King County, WA was 
examined with the hypothesis that an inverse association exists between histories of cancer and 
dementia in the parents of participants. The associations between a personal history of cancer in 
the participant with incident dementia, and that between a family history of cancer in relation to 
incident dementia, are presented elsewhere. 
 
Methods 
Study Design 
The Kame Project was a prospective cohort study of Japanese Americans over age 65 in 
King County, Washington from 1992 through 2001. Eighteen-hundred and thirty-five dementia-
free participants, or probands, completed the baseline questionnaire. Before coming to the study 
site, participants were asked to fill out a family tree of first-degree relatives. This was transposed 
by the interviewer into the questionnaire, where each family member was indicated separately. 
Cases of dementia discovered at the prevalence phase of the study were excluded from this 
analysis.7 Data were gathered for each family member from the non-demented participant on 
whether or not the family member experienced memory problems or had cancer. Further 
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information on the Kame Project’s prevalence and incidence phases have been published in 
detail elsewhere.7, 8 
 
Study Population  
This is a cross-sectional analysis examining the parents of Kame participants who were 
reported to have cancer and dementia histories. Parents with missing information on cancer 
status and/or dementia status (n = 155) and age at death (n = 436) were excluded from analyses. 
Further excluded were those who did not reach the age of 65 (n = 747), which is when late-onset 
AD/dementia begins. The final sample size included 2,332 parents.  
 
Cancer Case Ascertainment 
The family history question on cancer subdivided the disease into three categories: 
cancer, leukemia and Hodgkin’s disease. These three questions were combined into one derived 
cancer variable for analysis. Previous cancer-dementia studies also relied on cancer self- 
report.6, 18, 19 
 
Dementia Case Ascertainment 
Kame participants who indicated that a parent had a memory problem were asked to 
complete a separate memory grid. Specific questions were asked in order for the investigators to 
try to derive DSM criteria from their responses. We used four of these questions to determine if 
each parent was likely to have developed dementia: 1) whether the memory problem lasted for 6 
months or longer; 2) if the symptoms began gradually or suddenly; 3) how it progressed (give 
major response categories here); and 4) whether the symptoms interfered with work or social 
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functions. Three raters (ALS, ARB, JAM) independently assessed patterns of the four questions 
to determine if each parent had dementia. Agreement to divergent coding decisions were 
adjudicated by the three raters.  
All Kame cohort participants from whom the current study’s sample is drawn gave 
written informed consent. The Kame Project was approved by the University of Washington and 
University of South Florida Institutional Review Boards. 
 
Statistical Analyses 
 Sex and cancer status were compared between those parents judged to have had dementia 
and those judged not to have had dementia. using the chi-square test. Student’s t-test was used to 
assess the difference in age at death between these groups. A p-value below 0.05 was considered 
statistically significant for both tests. Logistic regression analyses were performed to assess 
crude associations of cancer, sex and age at death with dementia status.  A multivariate logistic 
model with dementia status in the parent as the dependent variable examined cancer status, with 
sex and age at death as covariates in the model. Data were analyzed using SAS 9.4 (SAS 
Institute Inc., Cary, NC).  
 
Results 
 There were 1,213 (52.0%) mothers and 1,119 (48.0%) fathers in the study (N = 2,332) 
(Table 3.1).  Fathers were more likely to be reported to have had a history of cancer, 53.4% 
versus 46.6% for mothers (P = 0.0001). The mean age at death was 82.5 (84.3 for mothers and 
80.6 for fathers). The mean age at death was higher for those who did not have a reported history 
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of cancer (83.2 versus 79.8) (P = 0.02). The cancer prevalence for the entire sample was 459 
(19.7%) and the dementia prevalence was 251 (10.8%).  
 Table 3.2 shows the univariate and multivariate statistics for the association between 
history of cancer and history of dementia. When the variables were examined one at a time, we 
found a highly statistically significant inverse association between cancer in the parents and 
dementia in the parents. This association became somewhat weaker, but remained highly 
statistically significant (OR = 0.41, 95% CI = 0.25-0.66) when the model was adjusted for sex 
and age at death of the parents.  
 
Discussion 
Our results confirmed our a priori hypothesis that there is an inverse association between 
cancer status and dementia status. Our findings are consistent with the preexisting literature on 
dementia and cancer. Notably, the crude OR of 0.32 is almost identical to the 0.3 reported by 
Yamada et al.22 The main difference between that study and this one is that our confidence 
interval is much narrower. More importantly, the multivariate results revealed that participants 
with a history of cancer were 2.44 times less likely to have a history of dementia. The results 
were consistent when stratified by sex, although the association was stronger among men than 
women (P value significant, data not shown).  
The biological mechanism(s) for the cancer-dementia association have not been 
definitively identified. There appears to be changes in the cell cycle that cause cells to show a 
preference for either cell proliferation or cell death.24-27 The three genetic factors garnering the 
most intensive research interest are the PIN1 tumor suppressor, the tumor protein p53 enzyme 
and genes in the Wnt signaling pathway.24-27 Changes in the up- or down-regulation of PIN1, p53 
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and/or Wnt lead to differing consequences, including cell proliferation (cancer) or cell apoptosis 
(AD).25-28  These potential modifiers are associated with phosphorylated tau protein and Aβ 
plaques. Accumulation of Aβ and phophorylated tau aggregation eventually lead to neuronal 
death.27, 28 Both cancer and AD pathogenesis can be modified by epigenetic mechanisms such as 
aging, environmental toxins, diet and exercise.30, 31 All of these are known to be risk factors 
associated with cancer and dementia.  
The strengths of our study include a large sample size, reporting of family history of 
cancer and dementia by initially non-demented participants and a representative population of 
Japanese Americans living in King County, WA.7, 8 In our methodologically-standardized sister 
study in Japan,22 no adjustments were made for potential confounders. In our study, age at death 
and sex were adjusted in the multivariate models. The use of a memory grid in the Kame study 
was an additional strength, since it allowed us to get closer to a definition of dementia by DSM 
criteria. This study also had a more balanced proportion of parental sex than the previous study. 
However, the study has several limitations. Because there was a statistically significant 
difference between the age at which those with a history of cancer died (those with a parental 
history of cancer died younger), it is possible that there is differential survival based on age at 
death. This has been previously suggested in the literature.13, 37 Also, parents who became 
afflicted with cancer in previous decades would have had more limited treatment options. If this 
bias were present, we would expect that the inverse association we observed may be over-
estimated. However, there only appears to have been a small effect from such potential survival 
bias, as we controlled for age at death. Therefore, survival bias likely was not present to a great 
extent. Reporting bias is a limitation arising from the potential difficulty of Kame probands to 
accurately recall their parents’ medical history. One possibility is that probands may be more 
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concerned with their parents dying from cancer, such that they under-recalled the presence of 
memory complaints. This would weaken the observed association if this were the case. A further 
limitation is the absence of a temporal sequence, arising from the inability to differentiate which 
disease occurred first in this cross-sectional analysis. 
An additional explanation for our findings could be the presence of lead time bias. All 
participants in the Kame cohort were at least 65 years of age at baseline, and an incipient Kame 
dementia patient may have early signs of memory loss that are not diagnosable but still have an 
impact on their reporting of their family’s medical history. We performed a stratified analysis of 
Kame probands to investigate this possibility. The probands were stratified by incident dementia 
status. No differences were observed between these groups (data not shown).  
 This study’s results lend some of the strongest evidence for an inverse association 
between cancer and dementia. Epidemiologic studies in the United States, Sweden, Taiwan and 
Japan show consistent findings for this association. Our study, being focused on older Japanese 
Americans, suggests that the association holds for other ethnic groups in the United States. All 
studies to date have utilized data from pre-existing studies, which were not designed to assess the 
association between family history of cancer and dementia. Future longitudinal studies should 
specifically address the competing risks of these two diseases, and how their consequences affect 
the elderly. Environmental and lifestyle changes that currently increase risk for negative health 
outcomes through gene-environment interactions will need to be implemented on a community 
public health level, as well as with each individual in order to help prevent these increasingly 
prevalent and interrelated diseases.  
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Table 3.1. Baseline statistics of the Kame project parents. 
 
  No History History   
Kame Parents   of Cancer of Cancer   
BASELINE STATISTICS (n = 1,873) (n = 459)   
N = 2,332 n (%*) n (%*) n (%*) P-Value 
Sex       0.0001 
   Male 1,119 (48.0) 874 (46.7) 245 (53.4)   
   Female 1,213 (52.0) 999 (53.3) 214 (46.6)   
Age at death†       0.02 
  82.5 ± 9.2 83.2 ± 9.2 79.8 ± 8.5   
* Column percentages 
   † The statistics for age: mean ± standard deviation 
  
 
Table 3.2. Univariate & multivariate odds ratios (OR) and 95% confidence intervals for 
covariates in the model. 
 
 
    Univariate Multivariate 
Kame Parents     Statistics Model 
N = 2,332 n (%*) Dementia (%*) OR (95% CI) OR (95% CI) 
Cancer         
No 1,873 231 (12.3) 1 (referent) 1 (referent) 
Yes 459 20 (4.4) 0.32 (0.20-0.52) 0.41 (0.25-0.66) 
Sex         
Male 1,119 66 (5.9) 1 (referent) 1 (referent) 
Female 1,213 185 (15.3) 2.87 (2.14-3.85) 2.34 (1.73-3.16) 
Age at death       
      1.07 (1.05-1.09) 1.05 (1.04-1.07) 
* Row percentages  
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